Business Services Industry
Schaeffer's S&P 500 Index Hot Stocks Features PMC-Sierra, Gilead Sciences, Amgen, Guidant, and Tektronix
Business Wire, June 24, 2005
CINCINNATI -- Among the stocks featured in the June 24 edition of Schaeffer's S&P 500 Index Hot Stocks are PMC-Sierra (NASDAQ:PMCS), Gilead Sciences (NASDAQ:GILD), Amgen (NASDAQ:AMGN), Guidant(NYSE:GDT), and Tektronix (NYSE:TEK). Schaeffer's S&P 500 Index Hot Stocks is just one of the many free market commentaries written everyday at www.SchaeffersResearch.com - the home of Bernie Schaeffer and Schaeffer's Investment Research. For additional information about this report or to have it delivered to you free via email every day click on the following link. http://www.schaeffersresearch.com/redirect.aspx?CODE=PRSHS1M&PAGE=1.
Schaeffer's S&P 500 Index Hot Stocks for Friday, June 24, 2005:
A daily feature available on SchaeffersResearch.com is the "SPX Hot Stocks" column. Each afternoon, we will provide a list of the day's top-20 performing stocks in the S&P 500 Index (SPX - 1,193.38) as well as the bottom-20 names. Featured along with this table will be news that is moving some of the securities.
NOTE: Stocks trading under $5 per share have been eliminated from this listing of the top-20 and bottom-20 performing stocks.
U.S. stocks are spending the final trading hour of the week in the red, as the continued step higher in oil prices and weakness among several blue-chips inspired a round of selling pressure. The SPX is off 0.64 percent and has dropped beneath the psychologically significant 1200 level. Only about 23 percent of its 500 members are hovering above breakeven heading into the close.
PMC-Sierra (NASDAQ:PMCS) came forward with some fundamental news on Friday, announcing 63 planned job cuts. The layoffs, which will be concentrated in the firm's research-and-development department, are in addition to 26 layoffs announced in May. In total, the elimination of these 89 positions will reduce the firm's total workforce by about 10 percent and trim operating expenses by $10 million to $12 million each year. The networking-chip company also noted that second-quarter revenue would be "at or near" the high end of its previously projected range between $70 million and $72 million. The stock has risen about three percent today on above-average volume.
Gilead Sciences (NASDAQ:GILD) slapped Roche Holding (RHHBY) with a notice of termination in an effort to maintain rights to its Tamiflu medication, which combats influenza. In the notification, GILD accused the Swiss company of poor marketing efforts that violated a 1996 licensing agreement. Roche disputed the claim, and asserted that it was not neglectful in its promotion of Tamiflu.
The biotechnology sector is one of a few outperforming groups in late Friday activity, as Genentech (DNA) completed its $408 million buyout of Biogen Idec's Oceanside, California plant. Amgen (NASDAQ:AMGN) is sharing in the fun, rising more than a percent on the day. AMGN is in need of a shake-up, as the stock has been trading in a sideways range between 55 and 65 since late 2003.
In a sea of red, Guidant (NYSE:GDT) has the dubious distinction of being the worst-performing SPX member this afternoon. The company, which is due to be acquired by Johnson & Johnson (JNJ), has found manufacturing defects in four models of its implantable defibrillating devices. As such, GDT officials warned doctors to begin discontinuing use of these faulty product lines. Not surprisingly, the stock gapped dramatically lower on heavy volume, slipping beneath its 20-month moving average as a result. Oddly enough, JNJ shares have managed to edge higher.
Tektronix (NYSE:TEK) said last night that fourth-quarter earnings totaled 24 cents per share. This figure was six cents below last year's results, and below analysts' consensus view. Excluding one-time costs, however, the firm banked 31 cents per share, edging out Wall Street's forecast by a penny. On Friday morning, the manufacturer of test and measurement equipment told CNBC interviewers that his company's earnings were "a little bit lumpy," and warned that the first-quarter period has historically been the firm's slowest.
Alcoa is a drag on the Dow Jones Industrial Average today, after announcing worldwide job cuts of 6,500, or five percent of its total staff, all of which will occur in the second quarter. The workforce reduction serves as part of the firm's overall restructuring plan, which aims to achieve annual savings of $150 million. In separate news, Longbow reduced its rating on the security to "neutral" from "buy."
Click the following link to see a Chart of the SPX 500 Index's Top-20 Percentage Gainers: http://www.schaeffersresearch.com/wire?ID=13487 .
Click the following link to see a Chart of the SPX 500 Index's Top-20 Percentage Losers: http://www.schaeffersresearch.com/wire?ID=13487 .
Take advantage of the timely Schaeffer commentaries by signing up for their free e-newsletters -- Opening View, Market Recap and Monday Morning Outlook. Click here to have the Schaeffer's commentaries delivered to you free via email every day. http://www.schaeffersresearch.com/redirect.aspx?CODE=PRSHS1M&PAGE=1 .
- 5 Rules for Immediate Annuities
- Death in the Family: 12 Things to Do Now
- Dumbest Things You Do With Your Money
- 6 Online Networking Mistakes to Avoid
- 401(k) Mistakes to Avoid
- 5 Economic Scenarios to Keep You Up at Night
- The Real ‘Best Places to Retire’
- Best Credit Cards for You
- 12 Tough Questions to Ask Your Parents
- The Real ‘Best Colleges’
- Home Buyer Tax Credit: How to Cash In
- Why You Shouldn't Bash Cash
- 8 Phony 'Bargains' and Better Alternatives
- Danger: 3 Debit Card Scams to Avoid
- 6 Myths About Gas Mileage
- 29 Fees We Hate Most
- Quick and Easy Ways to Boost Returns
- Best Stocks to Buy Now
- Lower Your Taxes: 10 Moves to Make Now
- New Jobs: 8 Lessons from Real-Life Career Switchers
- The New Job Market: Who Wins and Who Loses?
- Health Care Reform's Public Option: Everything You Need to Know
- Volunteer Work When Unemployed: Should You Work for Free?
- Whose Recovery Is This?
- Long-Term-Care Insurance: 4 Biggest Risks to Avoid
Most Recent Business Articles
- Psyadon Pharmaceuticals, Inc. Announces Regulatory Milestones and the Initiation of a Clinical Trial of Ecopipam in Lesch-Nyhan Disease
- Emergence of “Femtomedicine” - New Frontier of Biomed Sciences - Reported at First Global Congress on Nano Medicine
- Research and Markets: Ethiopia Power Market Outlook to 2020
- Research and Markets: Orphan Drugs in Asia-Pacific: from Designation to Pricing, Funding & Market Access
- Research and Markets: Now You See It - TV Program Sponsorship & Product Placement in China
Most Recent Business Publications
Most Popular Business Articles
- 7 tips for effective listening: productive listening does not occur naturally. It requires hard work and practice - Back To Basics - effective listening is a crucial skill for internal auditors
- FHM Features Anna Benson, Baseball's Hottest Wife
- Building a DNA database: the federal government has just enacted two bills related to DNA. The first would drive the collection of DNA from all infants. The second would attempt to prevent the DNA that is collected from being misused
- America's most wanted j-o-b-s - 10 hottest employment opportunities
- Developmental sequence in small groups


